Capital Allocation and Runway Strategy
Prioritize portfolio investments with disciplined runway logic, milestone based decision frameworks, and clear board level tradeoffs.

Yasser Hazzaa
Founder & Principal Consultant
Architecting financial discipline for biopharma inflection points. Empowering executive teams to navigate commercialization, financing, and portfolio decisions with institutional rigor and measurable outcomes.
Executive Credentials
$17B
Planning Scope
Bristol Myers Squibb
~600%
Market Cap Growth
MannKind Corporation
20%+
Reporting Cycle Reduction
Dashboard automation impact
150+
Global FP&A Community
Bristol Myers Squibb
25+
Years Finance Leadership
Bristol Myers Squibb and MannKind Corporation
2
Board Positions
TesoRx Pharma and Lipac Oncology; clinical stage companies
Services
On desktop, hover each service to reveal executive context. On mobile, details are visible by default.
Prioritize portfolio investments with disciplined runway logic, milestone based decision frameworks, and clear board level tradeoffs.
Translate operating performance into concise board narratives that align capital, risk, and forward strategy.
Prepare investor data rooms, integrated model packs, and executive Q&A narratives that accelerate financing conversations.
Establish executive finance cadence, elevate team execution, and strengthen governance without adding organizational drag.
Guide leadership transitions and enterprise value decisions with public-company rigor tailored to growth-stage life sciences teams.
Build decision ready planning, rolling forecast discipline, and driver based analysis for faster executive action.
Strengthen liquidity visibility, improve working capital discipline, and protect operating flexibility across milestones.
De risk transactions and protect margin through diligence frameworks, integration planning, and commercial controls.
Sharpen equity narrative, guidance readiness, and investor communications with institutional quality finance discipline.
Align pricing, payer assumptions, and launch economics into a finance framework leadership can execute with confidence.
A career defined by delivering measurable financial transformation for global biopharmaceutical organizations.
~600%
Market Cap Growth
MannKind Corporation
VP Finance, 2017 to 2025
Partnered with Executive Leadership Team (ELT) to achieve 600% growth in enterprise value through rigorous FP&A and capital strategy during a transformative seven-year growth cycle.
20%+
Reporting Cycle Reduction
MannKind Corporation
VP Finance
Optimized reporting workflows with Power BI automation; this reduced reporting cycle time by more than 20 percent and strengthened decision velocity.
150+
Global FP&A Community
Bristol Myers Squibb
FP&A COE Lead, 2015 to 2016
Built a global FP&A community driving process excellence and capability development across the organization.
$17B
Planning Scope
Bristol Myers Squibb
Director Corporate FP&A, 2011 to 2015
Led Long-Term Financial Plan and served as Global Finance Lead for Virology, Neuroscience, and Immuno-science franchises.
Strategic CFO leadership for biopharma at key inflection points: clinical milestones, commercialization, and financing. Board-ready reporting, capital allocation, and forecasting discipline grounded in Fortune 500 standards. Let's align your strategy to measurable value creation.
yasser.hazzaa@gmail.com
Phone
+1 (609) 865-8068
linkedin.com/in/yasserhazzaa
Fill out the form below to get started